Paid Clinical Trials Scottsdale
Discover 1,135 paid clinical trials in Scottsdale, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Observational StudyPancreatic Cancer Early Detection Consortium
Sponsor:
Arbor Research Collaborative for Health
Location:
Code:
NCT04970056
Conditions
Pancreas Cancer
Pancreas Cyst
Pancreatic Ductal Adenocarcinoma
Genetic Predisposition
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderA Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06817356
Conditions
Alcohol Use Disorder
Eligibility Criteria
Sex: All
Age: 21 - 65
Healthy Volunteers: Not accepted
Interventions
Mazdutide
Placebo
SAR444656Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Sponsor:
Sanofi
Location:
Code:
NCT06058156
Conditions
Atopic Dermatitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
SAR444656 (KT-474)
Placebo
PF-07220060 with LetrozoleStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Sponsor:
Pfizer
Location:
Code:
NCT06760637
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-07220060
letrozole
abemaciclib
palbociclib
ribociclib
IDE196 & CrizotinibIDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
Sponsor:
IDEAYA Biosciences
Location:
Code:
NCT05987332
Conditions
Metastatic Uveal Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IDE196
Crizotinib
Pembrolizumab
Ipilimumab
Nivolumab
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Observational StudyData Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.
Sponsor:
Fairtility
Location:
Code:
NCT06928337
Conditions
Fertility Disorders
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Accepted
Interventions
AI evaluation of oocytes.
GI-102, Pembrolizumab, T-DXdA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Sponsor:
GI Innovation, Inc.
Location:
Code:
NCT05824975
Conditions
Advanced Solid Tumor
Metastatic Solid Tumor
Soft Tissue Sarcoma (STS)
Platinum-resistant Ovarian Cancer (PROC)
Hepatocellular Carcinoma (HCC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
GI-102 subcutaneous (SC)
GI-102
doxorubicin
paclitaxel
bevacizumab
InebilizumabThe ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Sponsor:
University of Utah
Location:
Code:
NCT04372615
Conditions
Autoimmune Encephalitis
Encephalitis
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Inebilizumab
Placebo
Reduced Dose RadiotherapyReduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Sponsor:
Mayo Clinic
Location:
Code:
NCT06386315
Conditions
Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
Refractory Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent Non-Hodgkin Lymphoma
Refractory Indolent Non-Hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Computed Tomography
Endoscopic Procedure
Involved-site Radiation Therapy (3 Fractions)
Involved-site Radiation Therapy (12 Fractions)
Positron Emission Tomography
Observational StudyADVENT Post Approval Study
Sponsor:
Boston Scientific Corporation
Location:
Code:
NCT06431815
Conditions
Paroxysmal Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
FARAPULSEΓäó Pulsed Field Ablation System